Glenmark ’s Phase IIa study of atopic dermatitis drug shows improved symptoms

Glenmark Pharmaceuticals has reported positive results from the Phase IIa clinical trial of its investigational candidate GBR 830 in patients with atopic dermatitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news